UBS Group
PCSA icon

UBS Group’s Processa Pharmaceuticals PCSA Stock Holding History

UBS Group’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Buy
7,794
+5,263
+208% +$13.6K ﹤0.01% 8333
2026
Q1 		$6.39K Sell
2,531
-10,109
-80% -$27.6K ﹤0.01% 8693
2025
Q4 		$36.4K Buy
+12,640
New +$88.3K ﹤0.01% 7398
2025
Q3 		– Sell
-2,584
Closed -$13.2K – 10772
2025
Q2 		$13.2K Buy
2,584
+2,582
+129,100% +$17.2K ﹤0.01% 8706
2025
Q1 		$21 Sell
2
-314
-99% -$4.73K ﹤0.01% 10088
2024
Q4 		$6.99K Buy
316
+295
+1,405% +$8.32K ﹤0.01% 8512
2024
Q3 		$714 Buy
+21
New +$822 ﹤0.01% 8842
2024
Q2 		– Sell
-167
Closed -$9.89K – 9951
2024
Q1 		$9.89K Buy
167
+7
+4% +$555 ﹤0.01% 7261
2023
Q4 		$26.8K Buy
160
+159
+15,900% +$35.5K ﹤0.01% 6919
2023
Q3 		$177 Buy
+1
New +$189 ﹤0.01% 8742
2023
Q2 		– Sell
-45
Closed -$11.2K – 9455
2023
Q1 		$11.2K Buy
+45
New +$18.1K ﹤0.01% 7521
2022
Q2 		– Sell
-2
Closed -$3K – 10758
2022
Q1 		$3K Buy
+2
New +$3.81K ﹤0.01% 9468
2021
Q4 		– Sell
-1
Closed -$3.1K – 10010
2021
Q3 		$5K Buy
+1
New +$3.42K ﹤0.01% 8549
2021
Q2 		– Hold
0
– – – 9698

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

UBS Group's PCSA Position: Q2 2026 in Review

UBS Group increased its Processa Pharmaceuticals (PCSA) stake by 208% in Q2 2026, buying an estimated $13.6K and bringing the position to 7,794 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #8333.

UBS Group first reported a position in PCSA in Q3 2021 and has held it in 13 quarters since. The position peaked at $36.4K in Q4 2025. 11 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

  • UBS Group held 7,794 shares of Processa Pharmaceuticals worth $15K as of Q2 2026.
  • UBS Group bought 5,263 Processa Pharmaceuticals shares in Q2 2026, an estimated $13.6K.
  • Processa Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8333 holding.
  • UBS Group first reported a position in Processa Pharmaceuticals in Q3 2021 and has held it in 13 quarters since.
  • UBS Group's Processa Pharmaceuticals position peaked at $36.4K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.